Groundbreaking Platform Technology for Specific Binding to Necrotic Cells
AssigneeHQ Medical Netherlands B.V.
InventorsMarkwin Hendrik Maring, Clemens Waltherus Gerardus Lowik, Ermond Reijer Van Beek
Life of this patent
Estimating the term…
Abstract
A system comprising a targeting molecule for binding necrotic cells; to the system for use as a medicament; to use of the system for diagnosis; to the system for use in treatment of diseases involving necrotic cell death, to a dosage comprising the system; to a method for determining localization of the composition within a sample using said system; and, to a method for treatment of cancers and/or diseases involving necrotic cell death using said system. In particular the invention relates to compositions targeting necrotic cells.
Claims12
A system comprising a targeting molecule for binding necrotic cells, the targeting molecule being a cyanine that is cell membrane impermeant, is non-activated, is capable of non-covalently binding to intracellular proteins wherein the targeting molecule is neutral or negatively charged, wherein the targeting molecule is selected from:
- HQ4, HQ5, HQ6, HQ7, ICG, ZW800, L7, L11, CY3, CY3b, CY3.5, CY5, Dy 676, Dy 681, Dy 731, Dy 751 and Dy 776;
- and does not significantly bind to DNA,
- wherein the system further comprises one or more of:
- (i) an agent selected from an imaging compound, a therapeutic compound, and a release factor;
- (ii) a vehicle that is effective for transporting an/the agent;
- and
- (iii) an in the body non-reactive molecule being capable of interacting with a counterpart.
A system comprising a targeting molecule for binding necrotic cells, the targeting molecule being a cyanine that is cell membrane impermeant, is non-activated, is capable of non-covalently binding to intracellular proteins wherein the targeting molecule is neutral or negatively charged, and does not significantly bind to DNA,
- wherein the system further comprises one or more of:
- (i) an agent selected from an imaging compound, a therapeutic compound, and a release factor;
- (ii) a vehicle that is effective for transporting an/the agent;
- and
- (iii) an in the body non-reactive molecule being capable of interacting with a counterpart for use as a medicament.
Use of a system comprising a targeting molecule for binding necrotic cells, the targeting molecule being a cyanine that is cell membrane impermeant, is non-activated, is capable of non-covalently binding to intracellular proteins wherein the targeting molecule is neutral or negatively charged, and does not significantly bind to DNA,
- wherein the system further comprises one or more of:
- (i) an agent selected from an imaging compound, a therapeutic compound, and a release factor;
- (ii) a vehicle that is effective for transporting an/the agent;
- and
- (iii) an in the body non-reactive molecule being capable of interacting with a counterpart, in a diagnostic method selected from MRI, SPECT, PET, RFA (Radio Frequency Ablation), CT, Raman spectroscopy, Ultrasound, Optical and Opto-acoustic.
A system comprising a targeting molecule for binding necrotic cells, the targeting molecule being a cyanine that is cell membrane impermeant, is non-activated, is capable of non-covalently binding to intracellular proteins wherein the targeting molecule is neutral or negatively charged, and does not significantly bind to DNA,
- wherein the system further comprises one or more of:
- (i) an agent selected from an imaging compound, a therapeutic compound, and a release factor;
- (ii) a vehicle that is effective for transporting an/the agent;
- and
- (iii) an in the body non-reactive molecule being capable of interacting with a counterpart for use in the treatment of diseases involving necrotic cell death, including infarcts or ischemic injury, such as Myocardial infarct, stroke, and kidney, trauma, such as in a brain, a muscle, a bone, infections or inflammation, such as septic shock, rheumatoid arthritis, and osteonecrosis, degenerative diseases, such as Alzheimer, Parkinson dementia, plaques, such as arteriosclerotic, and amyloid, and Diabetes.
Dosage for detection and/or treatment of cancers and/or diseases involving necrotic cell death comprising an effective amount of a system comprising a targeting molecule for binding necrotic cells, the targeting molecule being a cyanine that is cell membrane impermeant, is non-activated, is capable of non-covalently binding to intracellular proteins, wherein the targeting molecule is neutral or negatively charged, and does not significantly bind to DNA,
- wherein the system further comprises one or more of:
- (i) an agent selected from an imaging compound, a therapeutic compound, and a release factor;
- (ii) a vehicle that is effective for transporting an/the agent;
- and
- (iii) an in the body non-reactive molecule being capable of interacting with a counterpart.
A method for determining localization within a sample, said sample comprising a population of cells comprising necrotic cells, comprising:
- (a) providing a system comprising a targeting molecule for binding necrotic cells, the targeting molecule being a cya-nine that is cell membrane impermeant, is non-activated, is capable of non-covalently binding to intracellular proteins, wherein the targeting molecule is neutral or negatively charged, and does not significantly bind to DNA,
- wherein the system further comprises one or more of:
- (i) an agent selected from an imaging compound, a therapeutic compound, and a release factor;
- (ii) a vehicle that is effective for transporting an/the agent;
- and
- (iii) an in the body non-reactive molecule being capable of interacting with a counterpart;
- (b) performing one or more measurements on the sample with at least a first suitable imaging technique providing a value or values, and;
- (c) analysing said value or values of the measurement to determine localization, optionally by comparison with a set of reference values.
A method for treatment of cancers and/or dis-eases involving necrotic cell death comprising:
- (a) administering a system comprising a targeting molecule for binding necrotic cells, the targeting molecule being a cyanine that is cell membrane impermeant, is non-activated, is capable of non-covalently binding to intracellular proteins, wherein the targeting molecule is neutral or negatively charged, and does not significantly bind to DNA,
- wherein the system further comprises one or more of:
- (i) an agent selected from an imaging compound, a therapeutic compound, and a release factor;
- (ii) a vehicle that is effective for transporting an/the agent;
- and
- (iii) an in the body non-reactive molecule being capable of interacting with a counterpart, wherein the composition com-prises one or more therapeutic compound(s)
- (b) determining localization of the composition within the cancer and/or necrotic tissue
- (c) activating release of at least the therapeutic com-pound(s) from the vehicle and/or activating the therapeutic compound(s).
Dependencies are inferred from the claim text.